First-in-man trial of TransCon CNP in healthy volunteers

Trial Profile

First-in-man trial of TransCon CNP in healthy volunteers

Phase of Trial: Phase I

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs TransCon CNP (Primary)
  • Indications Achondroplasia
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 11 Jan 2018 New trial record
    • 08 Jan 2018 According to an Ascendis Pharma media release, the company has recently initiated the regulatory process in Australia to enable this trial. The company expects to initiate dosing the subjects in the second quarter of 2018 with top-line data to be announced in the fourth quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top